Get notified when MIRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (unchanged) — Substantial doubt about ability to continue as going concern persists despite extended cash runway to Q1 2027.
- Related Party (new) — Completed acquisition of related-party entity SKNY Pharmaceuticals, now reporting equity method losses of $92K in Q1 2026.
MIRA: net income -$1.2M. MIRA completes SKNY acquisition, advances Ketamir-2 to Phase 2a prep, extends cash to Q1 2027
Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~2 min read
Key Changes
-
high
Ketamir-2 Phase 1 dosing completed across all cohorts with no serious adverse events or dose-limiting toxicities; Phase 2a trial in chemotherapy-induced neuropathy planned for H1 2026.
MD&A: Clinical Development verify on EDGAR → -
high
Completed acquisition of related-party SKNY Pharmaceuticals (Sept 2025), adding SKNY-1 weight management/addiction candidate to pipeline; company now reports equity method investment losses.
MD&A: Acquisitions verify on EDGAR → -
high
Cash runway extended to Q1 2027 (from Q4 2025 baseline) with $4.8M on hand, though going concern warning persists; Nasdaq equity deficiency notice from April 2025 no longer mentioned.
MD&A: Liquidity verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.
Partner
Trade MIRA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify